Information on EC 2.7.1.91 - sphinganine kinase

New: Word Map on EC 2.7.1.91
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY hide
2.7.1.91
-
RECOMMENDED NAME
GeneOntology No.
sphinganine kinase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
ATP + sphinganine = ADP + sphinganine 1-phosphate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phospho group transfer
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
ceramide degradation
-
-
Metabolic pathways
-
-
sphingolipid biosynthesis (plants)
-
-
Sphingolipid metabolism
-
-
sphingolipid recycling and degradation (yeast)
-
-
sphingosine and sphingosine-1-phosphate metabolism
-
-
sphingosine metabolism
-
-
SYSTEMATIC NAME
IUBMB Comments
ATP:sphinganine 1-phosphotransferase
-
CAS REGISTRY NUMBER
COMMENTARY hide
50864-48-7
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
isozymes SgkA and SgkB encoded by the genes sgkA and sgkB
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
plant
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
ATP + (2R)-2-amino-2-[5-(4-octylphenyl)-1H-imidazol-2-yl]propan-1-ol
ADP + (2R)-2-amino-2-[5-(4-octylphenyl)-1H-imidazol-2-yl]propyl dihydrogen phosphate
show the reaction diagram
ATP + (2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutan-1-ol
ADP + (2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl dihydrogen phosphate
show the reaction diagram
-
isoform SPHK2 is 6fold more efficient than SPHK1 in phosphorylating
product is a nanomolar agonist of sphingosine 1-phsphate receptor 1, whereas the (2S)-enantiomer is much weaker
-
?
ATP + (2R,3R)-3-amino-5-(4-heptoxyphenyl)-3-methylpentan-2-ol
ADP + (2R,3R)-3-amino-5-(4-heptoxyphenyl)-3-methylpentan-2-yl dihydrogen phosphate
show the reaction diagram
-
no substrate for SPHK1, phosphorylated by SPHK2 at low rates
product is a potent agonist of sphingosine 1-phsphate receptor 1
-
?
ATP + 1-O-hexadecyl-2-deoxy-2-amino-sn-glycerol
ADP + 1-O-hexadecyl-2-deoxy-2-amino-sn-glycerol 3-phosphate
show the reaction diagram
-
isozyme SPHK2, 10fold lower activity with isozyme SPHK1
-
-
?
ATP + 2-amino-2-[4-(4-octylphenyl)-1,3-oxazol-2-yl]propan-1-ol
ADP + 2-amino-2-[4-(4-octylphenyl)-1,3-oxazol-2-yl]propyl dihydrogen phosphate
show the reaction diagram
ATP + 2-amino-2-[5-(4-octylphenyl)-1,2,4-oxadiazol-3-yl]propan-1-ol
ADP + 2-amino-2-[5-(4-octylphenyl)-1,2,4-oxadiazol-3-yl]propyl dihydrogen phosphate
show the reaction diagram
ATP + 4,8-sphingadienine
ADP + 4,8-sphingadienine 1-phosphate
show the reaction diagram
-
high activity
-
-
ir
ATP + biotinyl-D-erythro-sphingosine
ADP + biotinyl-D-erythro-sphingosine 1-phosphate
show the reaction diagram
-
-
-
?
ATP + D-erythro-dihydrosphingosine
ADP + D-erythro-dihydrosphingosine 1-phosphate
show the reaction diagram
the activity of longrSK1 towards dihydrosphingosine is about 3.6fold higher than that of rSK1
-
-
?
ATP + D-erythro-sphingosine
ADP + D-erythro-sphingosine 1-phosphate
show the reaction diagram
ATP + DELTA4-unsaturated long chain sphingosine
ADP + DELTA4-unsaturated long chain sphingosine 1-phosphate
show the reaction diagram
-
high activity
-
-
ir
ATP + dihydrosphingosine
ADP + dihydrosphingosine 1-phosphate
show the reaction diagram
ATP + DL-threo-dihydrosphingosine
ADP + DL-threo-dihydrosphingosine 1-phosphate
show the reaction diagram
ATP + fluorescein-labeled sphingosine
ADP + fluorescein-labeled sphingosine 1-phosphate
show the reaction diagram
-
-
-
-
?
ATP + FTY720
ADP + ?
show the reaction diagram
-
-
-
-
?
ATP + FTY720
ADP + FTY720 1-phosphate
show the reaction diagram
ATP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
ADP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine 1-phosphate
show the reaction diagram
-
-
-
-
?
ATP + phytosphingosine
ADP + phytosphingosine 1-phosphate
show the reaction diagram
ATP + sphinganine
ADP + sphinganine 1-phosphate
show the reaction diagram
ATP + sphingosine
ADP + sphingosine 1-phosphate
show the reaction diagram
GTP + sphinganine
GDP + sphinganine 1-phosphate
show the reaction diagram
-
isozyme SPHK1
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
ATP + D-erythro-sphingosine
ADP + D-erythro-sphingosine 1-phosphate
show the reaction diagram
ATP + dihydrosphingosine
ADP + dihydrosphingosine 1-phosphate
show the reaction diagram
Q9VYY8, Q9VZW0
C14 and C16 dihydrosphingosine substrates
-
-
?
ATP + phytosphingosine
ADP + phytosphingosine 1-phosphate
show the reaction diagram
ATP + sphinganine
ADP + sphinganine 1-phosphate
show the reaction diagram
ATP + sphingosine
ADP + sphingosine 1-phosphate
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
GTP
-
utilized by isozyme SPHK1
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Cu
-
high affinity copper-binding protein
KCl
-
activates
Na+
-
increasing NaCl concentration stimulates activity
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R)-2-amino-4-(4-octylphenyl)butan-1-ol
-
i.e. (R)-2-amino-4-(4-octylphenyl)butan-1-ol, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
(2R,3S)-2-[[(4-octylphenyl)amino]methyl]pyrrolidin-3-ol
-
inhibition of isoform Sk1
(2R,3S)-3-amino-4-morpholin-4-yl-1-phenylbutan-2-ol
-
i.e. (2R,3S)-3-amino-4-morpholino-1-phenylbutan-2-ol, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
(2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol
-
potent, water-soluble, isoenzyme-specific inhibitor of SphK1. The inhibitor decreases growth and survival of human leukemia U937 and Jurkat cells, and enhances apoptosis and cleavage of Bcl-2. Lethality of SK1-I is reversed by caspase inhibitors and by expression of Bcl-2. The specific inhibitor of SphK1 warrants attention as potential addition to the therapeutic armamentarium in leukemia
(2R,3S,4E)-N-methyl-5-(4-pentylphenyl)-2-aminopent-4-ene-1,3-diol
(2S)-2-amino-N-(4-octylphenyl)-4-hydroxybutanamide
-
inhibition of isoform Sk1
(2S,3R)-2-amino-4-(4-octylphenyl)butane-1,3-diol
-
i.e. (2S,3R)-2-amino-4-(4-octylphenyl)butane-1,3-diol, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
(2S,3R)-2-amino-N-(4-octylphenyl)-3-hydroxybutanamide
-
inhibition of isoform Sk1
(2S,3R,4E)-2-(dimethylamino)octadec-4-ene-1,3-diol
inhibits both isoforms SK1 and SK2. Treatment triples the levels of isoform SK1 mRNA, but only slightly increases isoform SK2 expression; inhibits both isoforms SK1 and SK2. Treatment triples the levels of isoform SK1 mRNA, but only slightly increases isoform SK2 expression
(2S,3S)-2-amino-4-(4-octylphenyl)butane-1,3-diol
-
i.e. (2S,3S)-2-amino-4-(4-octylphenyl)butane-1,3-diol, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
(2S,3S)-3-hydroxy-N-(4-octylbenzyl)pyrrolidine-2-carboxamide
-
inhibition of isoform Sk1
(2S,3S)-3-hydroxy-N-(4-octylphenyl)pyrrolidine-2-carboxamide
-
inhibition of isoform Sk1
(S)-FTY720 vinylphosphonate
2-(4-hydroxyanilino)-4-(4-chlorophenyl)thiazole
2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole
2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole
3-O-sulfogalactosylceramide
-
endogenous glycolipid sulfatide, binds to and inhibits the activity of isoform Sphk2 and the closely related ceramide kinase Cerk, but not isoform Sphk1. The lipid binding domain is mapped to the N-terminus of Sphk2, residues 1-175, a region of sequence that is absent in Sphk1, but aligns with a pleckstrin homology domain in Cerk
5-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)tricyclo[3.3.1.13,7]decane-2-carboxamide
selective inhibition of isoform SK2
5-(4-chlorophenyl)-N-[2-(3,4-dihydroxyphenyl)ethyl]tricyclo[3.3.1.13,7]decane-2-carboxamide
inhibits both isoforms SK1 and SK2; inhibits both isoforms SK1 and SK2
B-5354c
B5354c
-
-
bovine serum albumin
camptothecin
-
-
Cu2+
-
-
Cutsum
-
detergent, required for sphinganine suspension, 0.05 mg/ml gives optimal rates, inhibition above 1 mg/ml
-
D(+)threo-Sphinganine
D,L-threo-dihydrosphingosine
dihydrosphingosine
dimethylsphingosine
DL-threo-dihydrosphinganine
-
competitive inhibitor
DL-threo-dihydrosphingosine
docetaxel
erythro-dihydrosphingosine
F-12509A
Fe2+
-
-
FTY720
galactosylceramide
-
0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity
galactosylceramide 3-sulphate
-
0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity
L(-)erythro-Sphinganine
-
-
L(-)threo-Sphinganine
L-erythro-sphingosine
-
0.005 mM, 41% inhibition; 0.005 mM, 43% inhibition
Melatonin
-
melatonin decreases enzymic activity in PC-3 cells during hypoxia. In addition, Melatonin inhibits the stability of hypoxia inducible factor 1alpha in a time- and concentration-dependent manner and suppresses AKT/glycogen synthase kinase-3beta signaling pathway
N,N,N-trimethylsphingosine
-
-
N,N-dimethylsphingosine
N-((2S,3S)-1,3-dihydroxy-4-phenylbutan-2-yl)tridecanamide
-
i.e. N-((2S,3S)-1,3-dihydroxy-4-phenylbutan-2-yl)tridecanamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-cyclohexylacetamide
selective inhibition of isoform SK1
N-ethylmaleimide
-
-
N-[(1R)-1-(hydroxymethyl)-3-phenylpropyl]tridecanamide
-
i.e. N-((R)-1-hydroxy-4-phenylbutan-2-yl)tridecanamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1R)-3-phenyl-1-(pyrrolidin-1-ylmethyl)propyl]decanamide
-
i.e. N-((R)-4-phenyl-1-(pyrrolidin-1-yl)butan-2-yl)decanamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S)-1-methyl-3-phenylpropyl]hexadecanamide
-
i.e. N-((R)-1-hydroxy-4-phenylbutan-2-yl)palmitamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)-3-phenylpropyl]hexadecanamide
-
i.e. N-((2S,3R)-1,3-dihydroxy-4-phenylbutan-2-yl)palmitamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)-3-phenylpropyl]tridecanamide
-
i.e. N-((2S,3R)-1,3-dihydroxy-4-phenylbutan-2-yl)tridecanamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2R)-2-hydroxy-3-phenyl-1-(pyrrolidin-1-ylmethyl)propyl]octadecanamide
-
i.e. N-((2S,3R)-3-hydroxy-4-phenyl-1-(pyrrolidin-1-yl)butan-2-yl)stearamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-3-phenylpropyl]hexadecanamide
-
i.e. N-((2S,3S)-1,3-dihydroxy-4-phenylbutan-2-yl)palmitamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2S)-2-hydroxy-1-(morpholin-4-ylmethyl)-3-phenylpropyl]decanamide
-
i.e. N-((2S,3S)-3-hydroxy-1-morpholino-4-phenylbutan-2-yl)decanamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2S)-2-hydroxy-3-phenyl-1-(pyrrolidin-1-ylmethyl)propyl]decanamide
-
i.e. N-((2S,3S)-3-hydroxy-4-phenyl-1-(pyrrolidin-1-yl)butan-2-yl)decanamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
N-[(1S,2S)-2-hydroxy-3-phenyl-1-(pyrrolidin-1-ylmethyl)propyl]octadecanamide
-
i.e. N-((2S,3S)-3-hydroxy-4-phenyl-1-(pyrrolidin-1-yl)butan-2-yl)stearamide, synthetic sphingosine analogue, specific inhibition of isozymes SphK1 and SphK2
p-chloromercuribenzoate
-
-
phosphatidylinositol 4,5-bisphosphate
-
0.01 mM, isoform SphK2, 60% of initial activity, isoform SphK1, 90% of initial activity
phosphatidylinositol 4-phosphate
-
0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity
phytosphingosine
-
0.0025 mM, 21% inhibition; 0.0025 mM, 64% inhibition
Ro-31-8220
-
-
S-12183a
-
-
-
S-12183b
-
-
-
SKI-II
-
isoform Sk1-specific inhibitor. Treatment markedly attenuates 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid-induced endothelial cell proliferation. 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid-induced activation of Akt kinase and transactivation of the epidermal growth factor receptor are also inhibited by SKI-II
sphingosine kinase inhibitor
-
can influence co-stimulatory molecules (CD40, CD80, CD86 and MHC class II) and cytokine production (IL-12 and IL-10) in murine bone marrow-derived dendritic cells. Sphingosine kinase inhibitor significantly inhibits co-stimulatory molecules in dendritic cells. Sphingosine kinase inhibitor suppresses IL-12 production by dendritic cells and IFN-gamma production by T cells
-
sphingosine kinase inhibitor II
-
-
-
Triton X-100
Zn2+
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid
-
treatment markedly augments SK activity in HUVECs. At the concentration of 1 mM, 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid increases SK activity by 110% and the maximal effect on SK activation is observed at 20 min after 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid addition. Inhibition of SK by a specific inhibitor, SKI-II, markedly attenuates 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid-induced endothelial cell proliferation. 11,12-Epoxy-(5Z,8Z,14Z)-eicosatrienoic acid-induced activation of Akt kinase and transactivation of the epidermal growth factor receptor are also inhibited by SKI-II
12-O-tetradecanoylphorbol-13-acetate
-
50 nM, maximum increase in activity after 24 h
bovine serum albumin
-
the enyzme activity is higher with substrate solubilized by bovine serum albumin compared to Triton X-100
-
Calmodulin
Ca2+-dependent binding of recombinant wild-type and mutant enzymes
camptothecin
-
0.003 mM camptothecin induces marked elevation of SPHK activity, reaching a maximal level with approximately 250% of the control untreated cells at 36 h
cardiolipin
-
;
cholesterol
-
0.01 mM, isoform SphK2, 107% of initial activity
Cutsum
-
detergent, required for sphinganine suspension, 0.05 mg/ml gives optimal rates, inhibition above 1 mg/ml
-
endothelin-1
-
1 nM, 2.4fold and 2.7fold increase of activity after 5 and 10 min, respectively
G-protein-coupled receptor agonists
-
-
-
galactosylceramide
-
0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity
galactosylceramide 3-sulfate
-
0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity
growth factors
-
platelet- and nerve-derived growth factors
-
heregulin
-
heregulin stimulates SphK1 activity only in filamin A-expressing A7 melanoma cells but not in filamin A-deficient cells and induces its translocation and colocalization with filamin A at lamellipodia. SphK1 is required for heregulin-induced migration, lamellipodia formation, activation of PAK1, and subsequent filamin A phosphorylation. Sphingosine 1-phosphate directly stimulates PAK1 kinase. Heregulin also induces colocalization of S1P1, the promotility sphingosine 1-phosphate receptor, but not S1P2, with SphK1 and filamin A at membrane ruffles
-
histamine
-
0.001 mM, up to 5fold increase of activity after 20 h
immunoglobulins E and G
-
-
-
jasplakinolide
latrunculin B
lipopolysaccharide
-
increases Sk1 transcription which is accompanied by increased SK activity and generation of sphingosine 1-phosphate. Sphingosine 1-phosphate is able to cause increases in COX-2 and PGE2 levels in RAW cells
muscarinic acetylcholine agonists
-
-
-
N,N-dimethylsphingosine
-
0.005 mM, activation to 106% of control
N-(1,3-dihydroxyisopropyl)-2-hexyl-3-oxo-decanamide
phorbol 12-myristate 13-acetate
;
phosphatidic acid
phosphatidylinositol
phosphatidylinositol 4-phosphate
-
0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity
phosphatidylinositol bisphosphate
-
;
phosphatidylserine
prolactin
-
-
-
sphingosine 1-phosphate
-
-
thrombin
-
stimulation of the lung epithelial cell line A-549 by thrombin leads to transient increase of SPHK1 activity and elevation of intracellular sphingosine 1-phosphate, abrogation of this stimulation by SPHK1-specific siRNA, pharmacological inhibition, or expression of a dominant-negative SPHK1 mutant blocks the response to thrombin. PAR-1 or thrombin-induced cytokine production and adhesion factor expression of human umbilical vein endothelial cells is also dependent on SPHK1
-
TNF-alpha
transforming growth factor beta1
-
5ng/ml
-
Triton X-100
tumor necrosis factor-alpha
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.063 - 0.1
ATP
0.0034 - 0.1
D(+)erythro-sphinganine
0.0034 - 0.0156
D-erythro-sphingosine
0.016
D-erythrosphinganine
-
as bovine serum albumin complex
0.02
DL-erythro-dihydrosphingosine
-
-
0.018 - 0.785
FTY720
1
L(-)threo-Sphinganine
1.7 - 3.6
nitrobenzoxadiazole-labeled sphingosine
0.09
sphinganine
-
-
0.005 - 0.108
sphingosine
additional information
additional information
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.01
(2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol
-
-
0.014 - 0.016
(2S,3R,4E)-2-(dimethylamino)octadec-4-ene-1,3-diol
0.0145
(S)-FTY720 vinylphosphonate
-
pH 7.4, 30C
0.0079 - 0.048
2-(4-hydroxyanilino)-4-(4-chlorophenyl)thiazole
0.0093
5-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)tricyclo[3.3.1.13,7]decane-2-carboxamide
pH not specified in the publication, temperature not specified in the publication
0.0031 - 0.0042
5-(4-chlorophenyl)-N-[2-(3,4-dihydroxyphenyl)ethyl]tricyclo[3.3.1.13,7]decane-2-carboxamide
0.001
ADP
-
-
0.0022 - 0.004
B-5354c
0.0037
B5354c
-
-
0.005 - 0.018
D,L-threo-dihydrosphingosine
0.005
dimethylsphingosine
-
-
0.01
DL-threo-dihydrosphingosine
-
-
0.004 - 0.0055
F-12509A
0.002
FTY720
-
pH 7.4, 30C
0.00033 - 0.012
N,N-dimethylsphingosine
0.00028
N-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-cyclohexylacetamide
pH not specified in the publication, temperature not specified in the publication
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00074
(2R,3S)-2-[[(4-octylphenyl)amino]methyl]pyrrolidin-3-ol
Homo sapiens
-
pH 7.5, 22C
0.00005
(2S)-2-amino-N-(4-octylphenyl)-4-hydroxybutanamide
Homo sapiens
-
pH 7.5, 22C
0.00065
(2S,3R)-2-amino-N-(4-octylphenyl)-3-hydroxybutanamide
Homo sapiens
-
pH 7.5, 22C
0.00043
(2S,3S)-3-hydroxy-N-(4-octylbenzyl)pyrrolidine-2-carboxamide
Homo sapiens
-
pH 7.5, 22C
0.000062
(2S,3S)-3-hydroxy-N-(4-octylphenyl)pyrrolidine-2-carboxamide
Homo sapiens
-
pH 7.5, 22C
0.0005
2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole
Homo sapiens
-
-
0.0024
dimethylsphingosine
200
KCl
0.0002
Ro-31-8220
Rattus norvegicus
-
at 37C, in the presence of 0.25% Triton X-100
0.0025
S-12183a
Homo sapiens
-
-
-
0.0016
S-12183b
Homo sapiens
-
-
-
0.00055
U-73122
Rattus norvegicus
-
at 37C, in the presence of 0.25% Triton X-100
0.0021
Y-27632
Rattus norvegicus
-
at 37C, in the presence of 0.25% Triton X-100
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000002
-
skeletal muscle homogenate
0.000018
-
sperm acrosome, SPHK1
0.00003
-
liver homogenate
0.00004 - 0.00005
-
homogenates of kidney, colon, stomach, pancreas, and heart
0.00006 - 0.00007
-
homogenates of testis, brain, and platelet
0.00009
-
homogenates of small intestine and spleen
0.00016
-
thymus homogenate
0.00024
-
lung homogenate
0.00375
-
-
0.184
native isozyme SK1 in cell extract
19.34
purified recombinant isozyme SK1
43.4
recombinant isozyme SK1 in cell extract of recombinant cells
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6.6 - 7.5
-
-
7.2
assay at; assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6 - 8.5
-
pH 6: about 55% of maximum activity, pH 8.5: about 40% of maximum activity
6 - 9
-
pH 6: about 35% of maximum activity, pH 9: about 70% of maximum activity
6.8 - 7.4
-
greater than 60% of maximum activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
gracilis muscle resistance artery. Pressure-dependent activation and translocation of isoform Sk1 by ERK1/2 is critically dependent on its serine225 phosphorylation site
Manually annotated by BRENDA team
-
LPS stimulates Sphk activity
Manually annotated by BRENDA team
-
melanoma B16 cells, variant F10, Swiss 3T3, balb/c 3T3 clone A31
Manually annotated by BRENDA team
-
thyroid cell
Manually annotated by BRENDA team
-
mouse calvaria osteoblast cell
Manually annotated by BRENDA team
-
follicular thyroid cell
Manually annotated by BRENDA team
-
neonatal cardiac myocyte
Manually annotated by BRENDA team
-
podocyte cell line
Manually annotated by BRENDA team
-
gracilis muscle resistance artery. Pressure-dependent activation and translocation of isoform Sk1 by ERK1/2 is critically dependent on its serine225 phosphorylation site
Manually annotated by BRENDA team
-
SPHK1, exclusively in the acrosome, spermatozoa contain 5 sphingosine 1-phosphate receptors
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
of sperm, SPHK1
-
Manually annotated by BRENDA team
-
enzymes cycles between trans-Golgi network and late endosomes, facing the cytosol
Manually annotated by BRENDA team
additional information